Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease
ALZHEIMER'S disease is the most common dementing illness and may be the fourth leading cause of death in the United States. It severely affects about 1.4 million Americans, and this number is predicted to increase fivefold in the next half century. 1 2 3 4 The current direct and indirect annual...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1990-08, Vol.323 (7), p.445-448 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 448 |
|---|---|
| container_issue | 7 |
| container_start_page | 445 |
| container_title | The New England journal of medicine |
| container_volume | 323 |
| creator | Thompson, Troy L Filley, Christopher M Mitchell, Wayne D Culig, Kathleen M LoVerde, Mary Byyny, Richard L |
| description | ALZHEIMER'S disease is the most common dementing illness and may be the fourth leading cause of death in the United States. It severely affects about 1.4 million Americans, and this number is predicted to increase fivefold in the next half century.
1
2
3
4
The current direct and indirect annual cost of Alzheimer's disease in the United States is estimated to be $24 billion to $48 billion.
4
,
5
The disease has no known cause or effective treatment, although a wide variety of therapeutic approaches have been considered.
6
One medication used for Alzheimer's disease is Hydergine (Sandoz brand of ergoloid mesylates), a preparation containing 0.333 . . . |
| doi_str_mv | 10.1056/NEJM199008163230704 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79898386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79898386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-890718771e6ecfef9d42a6e434607bca9af7e4f733c8d9b57238b18b2c6635ca3</originalsourceid><addsrcrecordid>eNp9kUlPwzAQhS0EgrL8AoQUgQQHFLA9jpcjS9lUlgOcI8cdg0uTlDgVKr-eoFYcEDCXGel98zSaR8g2o0eMZvL4rn9zy4yhVDMJHKiiYon0WAaQCkHlMulRynUqlIE1sh7jiHbFhFklq5xqbjLokdOBda9J7ZO-98FZN_uar2ZDbJ5DhUmokgfbBqzamLyH9iU5GX-8YCixOYjJeYhoI26SFW_HEbcWfYM8XfQfz67Swf3l9dnJIHXC6DbVhiqmlWIo0Xn0Zii4lShASKoKZ431CoVXAE4PTZEpDrpguuBOSsichQ2yP_edNPXbFGOblyE6HI9thfU05spoo0HLDtz9AY7qaVN1t-Wcg8kyUFkH7f0Fsc6GCw1AOwrmlGvqGBv0-aQJpW1mOaP5Vwj5LyF0WzsL72lR4vB7Z_H1Tj-c62UZ8wpH5b9un8xSiwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983248330</pqid></control><display><type>article</type><title>Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>New England Journal of Medicine</source><source>ProQuest Central</source><creator>Thompson, Troy L ; Filley, Christopher M ; Mitchell, Wayne D ; Culig, Kathleen M ; LoVerde, Mary ; Byyny, Richard L</creator><creatorcontrib>Thompson, Troy L ; Filley, Christopher M ; Mitchell, Wayne D ; Culig, Kathleen M ; LoVerde, Mary ; Byyny, Richard L</creatorcontrib><description>ALZHEIMER'S disease is the most common dementing illness and may be the fourth leading cause of death in the United States. It severely affects about 1.4 million Americans, and this number is predicted to increase fivefold in the next half century.
1
2
3
4
The current direct and indirect annual cost of Alzheimer's disease in the United States is estimated to be $24 billion to $48 billion.
4
,
5
The disease has no known cause or effective treatment, although a wide variety of therapeutic approaches have been considered.
6
One medication used for Alzheimer's disease is Hydergine (Sandoz brand of ergoloid mesylates), a preparation containing 0.333 . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199008163230704</identifier><identifier>PMID: 2082953</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Aged ; Alzheimer Disease - drug therapy ; Alzheimer's disease ; Bioavailability ; Biological Availability ; Capsules ; Clinical trials ; Clinical Trials as Topic ; Cognitive ability ; Consent ; Dementia ; Dihydroergotoxine - administration & dosage ; Dihydroergotoxine - therapeutic use ; Double-Blind Method ; Electroencephalography ; FDA approval ; Female ; Geriatrics ; Humans ; Intelligence ; Intelligence Tests ; Male ; Medical imaging ; Memory ; Mental disorders ; Middle Aged ; Neurodegenerative diseases ; Patients ; Psychiatric Status Rating Scales ; Psychiatry ; Wechsler Scales</subject><ispartof>The New England journal of medicine, 1990-08, Vol.323 (7), p.445-448</ispartof><rights>Copyright Massachusetts Medical Society Aug 16, 1990</rights><rights>Copyright Massachusetts Medical Society, Publishing Division Aug 16, 1990</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-890718771e6ecfef9d42a6e434607bca9af7e4f733c8d9b57238b18b2c6635ca3</citedby><cites>FETCH-LOGICAL-c498t-890718771e6ecfef9d42a6e434607bca9af7e4f733c8d9b57238b18b2c6635ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199008163230704$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223955375?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26102,27923,27924,52381,54063,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2082953$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Troy L</creatorcontrib><creatorcontrib>Filley, Christopher M</creatorcontrib><creatorcontrib>Mitchell, Wayne D</creatorcontrib><creatorcontrib>Culig, Kathleen M</creatorcontrib><creatorcontrib>LoVerde, Mary</creatorcontrib><creatorcontrib>Byyny, Richard L</creatorcontrib><title>Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>ALZHEIMER'S disease is the most common dementing illness and may be the fourth leading cause of death in the United States. It severely affects about 1.4 million Americans, and this number is predicted to increase fivefold in the next half century.
1
2
3
4
The current direct and indirect annual cost of Alzheimer's disease in the United States is estimated to be $24 billion to $48 billion.
4
,
5
The disease has no known cause or effective treatment, although a wide variety of therapeutic approaches have been considered.
6
One medication used for Alzheimer's disease is Hydergine (Sandoz brand of ergoloid mesylates), a preparation containing 0.333 . . .</description><subject>Aged</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Bioavailability</subject><subject>Biological Availability</subject><subject>Capsules</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Cognitive ability</subject><subject>Consent</subject><subject>Dementia</subject><subject>Dihydroergotoxine - administration & dosage</subject><subject>Dihydroergotoxine - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Electroencephalography</subject><subject>FDA approval</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Intelligence</subject><subject>Intelligence Tests</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Memory</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Neurodegenerative diseases</subject><subject>Patients</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Wechsler Scales</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUlPwzAQhS0EgrL8AoQUgQQHFLA9jpcjS9lUlgOcI8cdg0uTlDgVKr-eoFYcEDCXGel98zSaR8g2o0eMZvL4rn9zy4yhVDMJHKiiYon0WAaQCkHlMulRynUqlIE1sh7jiHbFhFklq5xqbjLokdOBda9J7ZO-98FZN_uar2ZDbJ5DhUmokgfbBqzamLyH9iU5GX-8YCixOYjJeYhoI26SFW_HEbcWfYM8XfQfz67Swf3l9dnJIHXC6DbVhiqmlWIo0Xn0Zii4lShASKoKZ431CoVXAE4PTZEpDrpguuBOSsichQ2yP_edNPXbFGOblyE6HI9thfU05spoo0HLDtz9AY7qaVN1t-Wcg8kyUFkH7f0Fsc6GCw1AOwrmlGvqGBv0-aQJpW1mOaP5Vwj5LyF0WzsL72lR4vB7Z_H1Tj-c62UZ8wpH5b9un8xSiwA</recordid><startdate>19900816</startdate><enddate>19900816</enddate><creator>Thompson, Troy L</creator><creator>Filley, Christopher M</creator><creator>Mitchell, Wayne D</creator><creator>Culig, Kathleen M</creator><creator>LoVerde, Mary</creator><creator>Byyny, Richard L</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19900816</creationdate><title>Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease</title><author>Thompson, Troy L ; Filley, Christopher M ; Mitchell, Wayne D ; Culig, Kathleen M ; LoVerde, Mary ; Byyny, Richard L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-890718771e6ecfef9d42a6e434607bca9af7e4f733c8d9b57238b18b2c6635ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Aged</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Bioavailability</topic><topic>Biological Availability</topic><topic>Capsules</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Cognitive ability</topic><topic>Consent</topic><topic>Dementia</topic><topic>Dihydroergotoxine - administration & dosage</topic><topic>Dihydroergotoxine - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Electroencephalography</topic><topic>FDA approval</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Intelligence</topic><topic>Intelligence Tests</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Memory</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Neurodegenerative diseases</topic><topic>Patients</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Wechsler Scales</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Troy L</creatorcontrib><creatorcontrib>Filley, Christopher M</creatorcontrib><creatorcontrib>Mitchell, Wayne D</creatorcontrib><creatorcontrib>Culig, Kathleen M</creatorcontrib><creatorcontrib>LoVerde, Mary</creatorcontrib><creatorcontrib>Byyny, Richard L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Troy L</au><au>Filley, Christopher M</au><au>Mitchell, Wayne D</au><au>Culig, Kathleen M</au><au>LoVerde, Mary</au><au>Byyny, Richard L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1990-08-16</date><risdate>1990</risdate><volume>323</volume><issue>7</issue><spage>445</spage><epage>448</epage><pages>445-448</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>ALZHEIMER'S disease is the most common dementing illness and may be the fourth leading cause of death in the United States. It severely affects about 1.4 million Americans, and this number is predicted to increase fivefold in the next half century.
1
2
3
4
The current direct and indirect annual cost of Alzheimer's disease in the United States is estimated to be $24 billion to $48 billion.
4
,
5
The disease has no known cause or effective treatment, although a wide variety of therapeutic approaches have been considered.
6
One medication used for Alzheimer's disease is Hydergine (Sandoz brand of ergoloid mesylates), a preparation containing 0.333 . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>2082953</pmid><doi>10.1056/NEJM199008163230704</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1990-08, Vol.323 (7), p.445-448 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79898386 |
| source | MEDLINE; EZB Electronic Journals Library; New England Journal of Medicine; ProQuest Central |
| subjects | Aged Alzheimer Disease - drug therapy Alzheimer's disease Bioavailability Biological Availability Capsules Clinical trials Clinical Trials as Topic Cognitive ability Consent Dementia Dihydroergotoxine - administration & dosage Dihydroergotoxine - therapeutic use Double-Blind Method Electroencephalography FDA approval Female Geriatrics Humans Intelligence Intelligence Tests Male Medical imaging Memory Mental disorders Middle Aged Neurodegenerative diseases Patients Psychiatric Status Rating Scales Psychiatry Wechsler Scales |
| title | Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A36%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20Efficacy%20of%20Hydergine%20in%20Patients%20with%20Alzheimer's%20Disease&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Thompson,%20Troy%20L&rft.date=1990-08-16&rft.volume=323&rft.issue=7&rft.spage=445&rft.epage=448&rft.pages=445-448&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199008163230704&rft_dat=%3Cproquest_cross%3E79898386%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983248330&rft_id=info:pmid/2082953&rfr_iscdi=true |